September 6, 2016
"I'm excited to talk about PEGPH20, which is a pegylated hyaluronidase. It was developed with the intent of actually making the stroma in pancreatic adenocarcinoma more permeable to agents, such as drugs. In preclinical models, this agent really has an impressive effect on the interstitial fluid pressure in the tumor microenvironment."
May 18, 2016
A national study led by Dr. Alan Venook has found that patients with metastatic colon cancer that develops on the left side of the colon survive significantly longer than those with cancer that develops on the right side. Additionally, the researchers learned that a standard drug used to treat colon cancer offers little benefit for patients whose cancer originated on the right side.
June 8, 2015
The combination of dabrafenib (Tafinlar), trametinib (Mekinist), and panitumumab (Vectibix) demonstrated an objective response rate (ORR) of 26% and a median progression-free survival (PFS) of 4.1 months in pretreated patients with BRAFV600E-mutated metastatic colorectal cancer (mCRC), according to findings from a phase I/II study presented at the 2015 ASCO Annual Meeting.
June 28, 2014
Alan P. Venook, MD discusses implications from the CALGB/SWOG 80405 trial on the targeted therapies administered in colorectal cancer. - See more at: http://www.onclive.com/conference-coverage/world-GI-2014/Dr-Venook-Discusses-Implications-of-the-80405-Study.
November 4, 2014
Genetically engineering tumors in mice, a technique that has dominated cancer research for decades, may not replicate important features of cancers caused by exposure to environmental carcinogens, according to a new study led by UC San Francisco scientists.
September 4, 2014
Katie Kelley, MD, a gastrointestinal oncologist at UC San Francisco, has received the 2014 Cancer Clinical Investigator Team Leadership Award from the National Cancer Institute (NCI).
June 1, 2014
Research led by a UC San Francisco investigator establishes a new benchmark in the treatment of patients with metastatic colorectal cancer and sets a new expectation for how long patients can live with the particularly lethal disease.
October 16, 2013
A UC San Francisco-led team of scientists has discovered that a gene mutation found in some bladder cancers is indicative of low-risk tumors that are unlikely to recur or progress after surgery.
November 29, 2012
A diagnosis of pancreatic cancer is particularly devastating since the prognosis for recovery is usually poor, with the cancer most often not detected until late stages.
August 21, 2012
A proposed new treatment to help HIV/AIDS patients suffering from Kaposi’s sarcoma, the most common form of cancer in people with HIV, is now one step closer to becoming a reality.
October 17, 2009
UCSF will host a free educational seminar on Saturday, Oct. 31 aimed at individuals with colorectal cancer -- a disease that kills nearly 50,000 Americans each year but is often curable if caught early. The seminar, "Conversations about Colorectal Cancer," will offer patients the opportunity ...
July 1, 2009
Members of UCSF's Gastrointestinal (GI) Oncology group are the inaugural recipients of the Helen Diller Family Quality Award, an honor that recognizes exceptional commitment to providing superior patient care. The group, led by gastrointestinal cancer expert Alan Venook, MD, was named the top performer in ...